DiGeorge Syndrome Drug Segmentation
The global DiGeorge syndrome drug market is segmented based on route of administration into oral and injectable, out of which, the oral administration segment is anticipated to garner major share during the forecast period in the market considering the ease and convenience of receiving the treatment. Based on end-user, the market is segmented into hospitals, homecare, speciality clinics and others, out of which speciality clinics are anticipated to hold a significant market share by the end of 2029 as these clinics are mostly preferred by patients owing to the availability of focused and specified treatment for the DiGeorge syndrome.
However, the treatment can be very expensive and long-stretched, causing financial and mental stress to the patients and their family. This can act as a restraint for the growth of the market. Additionally, with the expiry of patents of drugs from many companies, the chance of generic drugs being introduced in the market is high, which is further estimated, to hamper market growth over the forecast period.
Our in-depth analysis of the global market includes the following segments
|
By Route of administration |
|
|
By Therapy Type |
|
|
By End-Users |
|
